- The ETF's share price has been trailing the broader market as well as a peer for the last one year.
- However, the changes brought to the portfolio as part of an equal-weighted strategy, as well as addition of some key names are positives.
- Also, the ETF has historically delivered better performance and is subject to lower concentration risks.
- There should be a 16% long-term upside, using a growth estimate for the global biotechnology market, but with holdings involved in COVID variant cures, there are ingredients for further appreciation.
For further details see:
XBI: Portfolio Changes Offers Better Protection Against Volatility